SYNCOM FORMULATIONS share price has plunged 5% and is presently trading at Rs 21.9.
Meanwhile, the BSE HEALTHCARE index is at 43,216.4 (down 0.6%).
Among the top losers in the BSE HEALTHCARE index today are GRANULES INDIA (down 3.5%) and AJANTA PHARMA (down 2.5%).
ALEMBIC PHARMA (up 3.7%) and HIKAL CHEMIC (up 2.2%) are among the top gainers today.
Over the last one year, SYNCOM FORMULATIONS has moved up from Rs 8.8 to Rs 21.9, registering a gain of Rs 13.2 (up 150.5%).
On the other hand, the BSE HEALTHCARE index has moved up from 28,163.1 to 43,216.4, registering a gain of 53.5% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were SUVEN PHARMACEUTICALS (up 139.1%), Glenmark Pharma (up 115.6%) and GRANULES INDIA (up 113.2%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 80,914.4 (down 0.3%).
The top losers among the BSE Sensex today are MUNDRA PORT & SEZ (down 2.1%) and Tata Steel (down 1.7%). The most traded stocks in the BSE Sensex are Tata Steel and SBI.
In the meantime, NSE Nifty is at 24,755.7 (down 0.4%). ONGC and MUNDRA PORT & SEZ are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 65,780.3 to 80,914.4, registering a gain of 15,134.1 points (up 23.0%).
SYNCOM FORMULATIONS net profit grew 73.6% YoY to Rs 76 million for the quarter ended June 2024, compared to a profit of Rs 44 million a year ago. Net sales rose 45.8% to Rs 873 million during the period as against Rs 598 million in April-June 2023.
For the year ended March 2023, SYNCOM FORMULATIONS reported 1.4% increase in net profit to Rs 201 million compared to net profit of Rs 198 million during FY22. Revenue of the company grew 2.1% to Rs 2,243 million during FY23.
The current Price to earnings ratio of SYNCOM FORMULATIONS, based on rolling 12 month earnings, stands at 72.2.
Equitymaster requests your view! Post a comment on "SYNCOM FORMULATIONS Plunges 5%; BSE HEALTHCARE Index Down 0.6%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!